Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU1 | Q99519 | 16/20 | 0.79 |
| ▸ | NEU2 | Q9Y3R4 | 12/20 | 0.79 |
| ▸ | NEU4 | Q8WWR8 | 7/20 | 0.79 |
| ▸ | NEU3 | Q9UQ49 | 7/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neu5Ac2En SCHEMBL19454809 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL14080015 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL13839147 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL2631455 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL2619259 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL24387783 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL10054709 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL22263416 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| Neu5Ac2En SCHEMBL21125943 | 0.88 | NEU2 (1.00) | NEU1NEU2NEU4NEU3 | |
| SCHEMBL6018868 | 0.87 | NEU1 (0.73) | NEU1NEU2NEU4NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045535-B2 | Compounds useful for inhibiting paramyxovirus neuraminidase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20030187063-A1 | Compounds useful for inhibiting paramyxovirus neuraminidase | BIOCRYST PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | claimed |
| US-7045535-B2 | Compounds useful for inhibiting paramyxovirus neuraminidase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20030187063-A1 | Compounds useful for inhibiting paramyxovirus neuraminidase | BIOCRYST PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187063-A1 | Compounds useful for inhibiting paramyxovirus neuraminidase | SCN10A, NEU1, NEU4 | NEU1 2/4885NEU2 6/4885NEU4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.